drugset / Trial / NCT01165580

A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age

NCT01165580

Phase 1 Completed 17 enrolled Hoffmann-La Roche
NaSingle-groupOpen-labelPrevention

Summary

This open label study will assess the pharmacokinetics and the safety and tolerability of Valcyte (valganciclovir) powder for oral solution in neonatal and infant heart transplant patients \< 4 months of age.

Timeline

Start
2011-05
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Valganciclovir Small molecule Oral